Methyl 2-butyl-7-methylimidazo[4,5-c]pyridine-4-carboxylate | 149322-78-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: Methyl 2-butyl-7-methylimidazo[4,5-c]pyridine-4-carboxylate
• 英文别名: methyl 2-butyl-7-methyl-3H-imidazo[4,5-c]pyridine-4-carboxylate
• CAS: 149322-78-1
• 化学式: C₁₃H₁₇N₃O₂
• 分子量: 247.297
• InChiKey: DDISIHGVOZWFRR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  67.9
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Fused heterocyclic compounds, their production and use as angiotensin II antagonists
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP1327631A2

  公开（公告）日：2003-07-16

  Fused heterocyclic compounds of the formula (I): wherein R1 is an optionally substituted hydrocarbon residue which may be attached through a hetero atom; R2 is a group capable of forming an anion or a group convertible thereinto; R3 is an optionally substituted aromatic hydrocarbon or heterocyclic residue which contains at least one hetero atom; X is a direct bond or a spacer having an atomic length of two or less between the R3 group and the ring W group; W is an optionally substituted aromatic hydrocarbon or heterocyclic residue which contains at least one hetero atom; a,c and d are independently selected from the group consisting of one or two optionally substituted carbon atoms and one or two optionally substituted hetero atoms; b and e are independently selected from the group consisting of one optionally substituted carbon atom and one optionally substituted nitrogen atom; the dotted line is a bond to form one double bond; n is an integer of 1 or 2 and when a, which is an optionally substituted carbon atom, is taken together with R1, the following group: may form a ring group; provided that when is a benzimidazole, thieno[3,4-d]imidazole, or thieno[2,3-d]imidazole ring, at least one of the group: and R3 is an optionally substituted heterocyclic residue ; and the pharmaceutically acceptable salts thereof, have potent angiotensin II antagonistic activity and antihypertensive activity, thus being useful as therapeutic agents for treating circulatory system diseases such as hypertensive diseases, heart diseases (e.g. hypercardia, heart failure, cardiac infarction, etc.), strokes, cerebral apoplexy, nephritis, etc.

  式(I)的融合杂环化合物： 其中 R1 是可通过杂原子连接的任选取代的烃残基；R2 是可形成阴离子的基团或可转化为阴离子的基团；R3 是至少含有一个杂原子的任选取代的芳香烃或杂环残基；X 是 R3 基团与环 W 基团之间的直接键或原子长度为两个或更短的间隔键；W 是至少含有一个杂原子的任选取代的芳香烃或杂环残基； a、c 和 d 独立地选自由一个或两个任选取代的碳原子和一个或两个任选取代的杂原子组成的组；b 和 e 独立地选自由一个任选取代的碳原子和一个任选取代的氮原子组成的组；虚线是形成一个双键的键；n 是 1 或 2 的整数，当作为任选取代的碳原子的 a 与 R1 合在一起时，以下基团 可形成一个环状基团；但当 是苯并咪唑、噻吩并[3,4-d]咪唑或噻吩并[2,3-d]咪唑环时，至少有一个基团： 和 R3 是任选取代的杂环残基；其药学上可接受的盐类具有强效的血管紧张素 II 拮抗活性和降压活性，因此可作为治疗剂用于治疗循环系统疾病，如高血压疾病、心脏病（如心动过速、心力衰竭、心肌梗塞等）、中风、脑中风、肾炎等。
• Fused heterocyclic compounds, their production and use
  申请人：TAKEDA CHEMICAL INDUSTRIES, LTD.

  公开号：EP0518033B1

  公开（公告）日：2003-07-02
• US5389641A
  申请人：——

  公开号：US5389641A

  公开（公告）日：1995-02-14